The Effect of New Cross Linked Hyaluronan Gel on Quality of Life of Patients After Deep Infiltrating Endometriosis Surgery: A Randomized Controlled Pilot Study
New Cross Linked Hyaluronan Gel After Deep Infiltrating Endometriosis Surgery
Sponsors
Source
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Oversight Info
Has Dmc
No
Is Fda Regulated Drug
No
Is Fda Regulated Device
No
Brief Summary
Hyaluronan, a glycosaminoglycan found in connective tissues and extracellular matrix, has
been postulated to reduce postoperative adhesions, because of its unconditioned biological
functions at tissue repair but unfortunately it has a fluid nature that causes rapid
degradation, and it cannot effect long enough to work as an adhesion barrier.(10,11) For this
reason a New cross-linked hyaluronan (NCH) gel, that has higher viscosity compared to natural
hyaluronan has been developed by BioRegen Biomedical (Changzhou, Jiangsu, China). It has the
ability for gradually absorption within 1 to 2 weeks in vivo, which are the acquired repair
period and the critical time for adhesion formation. Although it seems evident that
endometriosis has a serious impact on the daily Quality of Life of women; comparable data for
the effect of adhesion barriers to patients who have had laparoscopic (Deep infiltrating
endometriosis) DIE surgery is missing.
Therefore a pilot randomised controlled study was conducted to evaluate the effect of NCH gel
on short term quality of life in patients who had undergone laparoscopic surgery due to DIE.
Detailed Description
A prospective 1:1 randomised placebo-controlled study was conducted in our department during
the study period January 2017-January 2019. All patients were included after obtaining
written, signed informed consent before participating. All of the procedures were performed
by the same surgery team who are experienced in minimally invasive (Deep infiltrating
endometriosis) DIE surgery. The study protocol was approved by the local Ethics Committee of
hospital (Approval number: 2017/04/35) 60 patients who were underwent for laparoscopic
surgery for the treatment of deep infiltrating endometriosis without bowel involvement were
recruited.
The inclusion criteria for this study were as follows, aged 18 to 45 years, and undergoing
laparoscopic surgery for suspicious of DIE and persistent pain irrespective to any medical
treatment. Patients were booked for follow-up visits at the 3rd and 6th month postoperative
months and wanted to fill the questionnaires.
The exclusion criteria for the study were as; acute or severe infection, autoimmune disease,
known/suspected intolerance or hypersensitivity to Hyaluronan or its derivatives, concurrent
use of a systemic anti-inflammatory or hormonal drug at least 3 months prior to the surgery,
clinical evidence of cancer; use of anticoagulant, fibrin glue, other thromboembolic agents,
or any other anti-adhesion agent during the procedure ,patients with surgically diagnosed
bowel involvement or need bowel resection, and who want to receive any postoperative hormonal
treatment.
Participants were allowed to voluntarily withdraw from the trial for any reason at any time,
and could be terminated by investigators owing to safety concerns, violations of
inclusion/exclusion criteria, or pregnancy.
Surgical procedure The patients were laid low lithotomy position under general anesthesia.
Patients were assigned at random to either the NCH gel or control group in a 1:1 ratio
through a computer based program. A standardised technic with 4 abdominal incision
laparoscopic approach with 10 mm umbilical trocar for the optic camera and three 5 mm
axillary ports for the surgical instruments were used. All of the surgeries initiated from
exploring the pelvic cavity, identification of the ureters and dissection transection of the
pelvic adhesion by 5 mm bipolar cautery used at 25 kw for coagulation mode and scissors. The
incision was begun on the left pelvic sidewall just cephalad to the last deposit. The
incision was then extended towards the uterus, lateral and parallel to the left uterosacral
ligament. The uterosacral ligament was pushed medially and down and the healthy tissues
including the ureter were pushed upwards and laterally away from the dissection. It then
transected the right utero-sacral ligament and was continued along the right pelvic sidewall
just lateral and above the right uterosacral ligament until it extends beyond all obvious
deposits. All of the endometriotic foci was grasped and pulled then undercut and freed so
that the whole lesion and a surrounding margin of healthy tissue was removed. After an
extensive bleeding control the Patients in the intervention group had 40 mL of HyaRegen NCH
gel instilled into the peritoneal cavity through a large-bore cannula following standard
laparoscopic procedures. The patients in the control group had 40 cc sterile saline solution
compatible with the body temperature. Operators could not be blinded to treatment allocation,
but the questionnaire assessors and the patients were blinded to treatment allocation.
Pre and Postoperative assessment of pain and quality of life A dedicated research assisted in
this study was asked the validated (visual analogue scale) VAS (dysmenorrhea, dyschezia,
dyspareunia, dysuria, and pelvic pain), (endometriosis health profile-5) EHP-5 and (short
form 12) SF-12 questionnaires before the day of the surgery. (12-14) A validated form of VAS
score was used and scored from 0: No pain to 10: the worst pain all in their lives in a
likert fashion. The VAS and (quality of life ) QoL questions were asked then in the 3rd and
6th month of during their follow up visits. A validated form of SF-12 that includes physical
functioning, role limitation due to physical health problems, bodily pain, general health,
vitality (energy/fatigue) social functioning, role limitations due to emotional problems and
mental health (psychological distress or wellbeing) were asked. The questions are scored and
analysed using a statistical algorithm to give two scores: the physical component summary and
the mental component summary.
A validated form of EHP-5 questionnaire was used to determine endometriosis related QoL of
the patients. EHP-5 consists of two parts: the first has a central questionnaire that
evaluate five dimensions - pain, control and powerlessness, emotional well-being, social
support, and self-image; and the second part measuring the areas of sexual intercourse, work,
relationship with children, feelings about medical professional, treatment and infertility.
Statistical analysis Data analysis was performed by using SPSS (IBM SPSS Statistics for
Windows, Version 20.0. Armonk, NY: IBM Corp.). A one-sample Kolmogorov-Smirnov test was
performed to analyse the distribution of clinical variables. The frequency and percentage of
the categorical variables and the mean, standard deviation, median and range values of the
continuous and ordinal variables were presented. The study groups were compared using Student
t test for parametric variables and Mann Whitney U test for the non-parametric variables. A
post-hoc sample size calculation was performed via a two-sided Z test (α=0.05, β=0.20) for
each study groups in order to obtain VAS scores as the primary outcome A p-value of < 0.05
was considered statistically significant for all calculations
Overall Status
Completed
Start Date
2017-01-01
Completion Date
2019-06-01
Primary Completion Date
2019-01-01
Phase
N/A
Study Type
Interventional
Primary Outcome
Measure |
Time Frame |
The preoperative and postoperative 6th month change of Visual Analogue Scale symptom score |
The preoperative and postoperative 6th month change in Visual Analogue Scale symptom score |
Secondary Outcome
Measure |
Time Frame |
Short Form-12 Quality of Life |
The preoperative and postoperative 6th month change of Short Form-12 Quality of Life questions were recorded considering follow up visits. |
Enrollment
60
Conditions
Intervention
Intervention Type
Drug
Intervention Name
Description
After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
Arm Group Label
HyaRegen NCH gel group
Other Name
bleeding control
Intervention Type
Drug
Intervention Name
Description
After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
Arm Group Label
Control
Other Name
bleeding control
Eligibility
Criteria
Inclusion Criteria:
- aged 18 to 45 years
- undergoing laparoscopic surgery for suspicious of DIE
- persistent pain irrespective to any medical treatment
Exclusion Criteria:
- acute or severe infection
- autoimmune disease
- known/suspected intolerance or hypersensitivity to hyaluronan or its derivatives
- concurrent use of a systemic anti-inflammatory or hormonal drug at least 3 months
prior to the surgery
- clinical evidence of cancer
- use of anticoagulant, fibrin glue, other thromboembolic agents
- use of any other anti-adhesion agent during the procedure
- patients with surgically diagnosed bowel involvement or need bowel resection
- patients who want to receive any postoperative hormonal treatment
Gender
Female
Minimum Age
18 Years
Maximum Age
45 Years
Healthy Volunteers
No
Overall Official
Last Name |
Role |
Affiliation |
Murat Ekin, MD |
Principal Investigator |
Bakırkoy Dr. Sadi Konuk Training and Research Hospital |
Verification Date
2019-07-01
Lastchanged Date
N/A
Firstreceived Date
N/A
Responsible Party
Responsible Party Type
Sponsor
Has Expanded Access
No
Condition Browse
Number Of Arms
2
Intervention Browse
Mesh Term
Hyaluronic Acid
Arm Group
Arm Group Label
Control
Arm Group Type
Placebo Comparator
Description
The patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
Arm Group Label
HyaRegen NCH gel group
Arm Group Type
Experimental
Description
In the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures.
Results Reference
Citation
Arcoverde FVL, Andres MP, Borrelli GM, Barbosa PA, Abrão MS, Kho RM. Surgery for Endometriosis Improves Major Domains of Quality of Life: A Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 2019 Feb;26(2):266-278. doi: 10.1016/j.jmig.2018.09.774. Epub 2018 Sep 20.
PMID
30244153
Firstreceived Results Date
N/A
Acronym
HYALOENDOQoL
Patient Data
Sharing Ipd
No
Firstreceived Results Disposition Date
N/A
Study Design Info
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Supportive Care
Masking
Double (Participant, Outcomes Assessor)
Study First Submitted
July 13, 2019
Study First Submitted Qc
July 16, 2019
Study First Posted
July 17, 2019
Last Update Submitted
July 16, 2019
Last Update Submitted Qc
July 16, 2019
Last Update Posted
July 17, 2019
ClinicalTrials.gov processed this data on December 13, 2019
Conditions
Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov,
conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Interventions
Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied.
Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Study Phase
Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions
that study is seeking to answer:
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.